drugset
drugset / Trial / NCT07844057

First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma

NCT07844057 ↗

Phase 2 Not yet recruiting 86 enrolled Annika Kurreck Deutsche Krebshilfe e.V., Bonn (Germany) · collabInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Phase II randomized trial evaluating modified FOLFIRINOX and FOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma

Timeline

Start
2026-10-01
Primary completion
2029-10-01
Completion
2034-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject fluorouracil Small molecule 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous
Subject Leucovorin Small molecule 400 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous

Indications

chemotherapy-induced toxicity metastatic malignant neoplasm small intestine adenocarcinoma